Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2024)

Fulcrum Therapeutics' (FULC) quarterly Restructuring Costs came in at $2.1 million in Q3 2024, up 5528.95% on a QoQ basis from -$38000.0 in Q4 2022.

Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2024) Analysis & Trends

Fulcrum Therapeutics (FULC) has 2 years of Restructuring Costs data on file, last reported at $2.1 million in Q3 2024.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to $2.1 million in Q3 2024; TTM through Dec 2025 was $2.1 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $2.1 million, changed N/A from the prior year.
Restructuring Costs for Q3 2024 stood at $2.1 million, up from -$38000.0 in the prior quarter.
Over the last five years, Restructuring Costs for FULC reached as high as $2.1 million in Q3 2024 and fell as low as -$38000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Fulcrum Therapeutics	285.43 Mn	285.43 Mn	-

Download Data